Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2009 Filed Mar 17, 2009 17:24 UTC |
MUELLER PETEREVP Drug Innov.& Realiz, CSO
|
SaleCommon Stock | 1,400 | $28.05 | $39,270.00 |
DisclosureSEC source: 0000875320-09-000017 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,356 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $28.05 (range $27.60 to $28.50). F4 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 16, 2009 Filed Mar 17, 2009 17:24 UTC |
MUELLER PETEREVP Drug Innov.& Realiz, CSO
|
Exercise / conversionCommon Stock | 2,400 | $9.69 | $23,256.00 |
DisclosureSEC source: 0000875320-09-000017 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:10 UTC |
MUELLER PETEREVP Drug Innov.& Realiz, CSO
|
Exercise / conversionStock Option · Derivative | 2,400 | $0.00 Strike: $9.69 | $0.00 |
DisclosureSEC source: 0000875320-09-000016 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 2,400 shares Expires 2014-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:10 UTC |
MUELLER PETEREVP Drug Innov.& Realiz, CSO
|
SaleCommon Stock | 2,400 | $32.88 | $78,912.00 |
DisclosureSEC source: 0000875320-09-000016 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,356 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $32.88 (range $32.55 to $33.14). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:10 UTC |
MUELLER PETEREVP Drug Innov.& Realiz, CSO
|
Exercise / conversionCommon Stock | 2,400 | $9.69 | $23,256.00 |
DisclosureSEC source: 0000875320-09-000016 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2009 Filed Feb 10, 2009 21:12 UTC |
Silva Paul MV.P. and Corporate Controller
|
SaleCommon Stock | 250 | $33.69 | $8,422.50 |
DisclosureSEC source: 0000875320-09-000015 · edgar.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,500 F1 · shares: Transaction made pursuant to Mr. Silva's company approved trading plan established under Rule 10b5-1. Read SEC document |
| February 06, 2009 Filed Feb 10, 2009 21:11 UTC |
SMITH IAN FEVP & CFO
|
Exercise / conversionStock Options · Derivative | 15,863 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0000875320-09-000014 · edgar.xml · derivative · entry 8 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,187 Underlying: Common Stock · 15,863 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| February 06, 2009 Filed Feb 10, 2009 21:11 UTC |
SMITH IAN FEVP & CFO
|
Exercise / conversionStock Options · Derivative | 18,000 | $0.00 Strike: $11.27 | $0.00 |
DisclosureSEC source: 0000875320-09-000014 · edgar.xml · derivative · entry 7 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2014-10-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| February 06, 2009 Filed Feb 10, 2009 21:11 UTC |
SMITH IAN FEVP & CFO
|
Exercise / conversionStock Options · Derivative | 7,349 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0000875320-09-000014 · edgar.xml · derivative · entry 6 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,349 shares Expires 2013-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| February 06, 2009 Filed Feb 10, 2009 21:11 UTC |
SMITH IAN FEVP & CFO
|
SaleCommon Stock | 41,212 | $35.00 | $1,442,420.00 |
DisclosureSEC source: 0000875320-09-000014 · edgar.xml · nonDerivative · entry 4 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,535 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan established under Rule 10b5-1. Read SEC document |
| February 06, 2009 Filed Feb 10, 2009 21:11 UTC |
SMITH IAN FEVP & CFO
|
Exercise / conversionCommon Stock | 15,863 | $10.41 | $165,133.83 |
DisclosureSEC source: 0000875320-09-000014 · edgar.xml · nonDerivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2009 Filed Feb 10, 2009 21:11 UTC |
SMITH IAN FEVP & CFO
|
Exercise / conversionCommon Stock | 18,000 | $11.27 | $202,860.00 |
DisclosureSEC source: 0000875320-09-000014 · edgar.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2009 Filed Feb 10, 2009 21:11 UTC |
SMITH IAN FEVP & CFO
|
Exercise / conversionCommon Stock | 7,349 | $15.60 | $114,644.40 |
DisclosureSEC source: 0000875320-09-000014 · edgar.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:13 UTC |
Graves KurtEVP, Chief Commercial Officer
|
GrantStock Option · Derivative | 54,375 | $0.00 Strike: $33.55 | $0.00 |
DisclosureSEC source: 0000875320-09-000003 · edgar.xml · derivative · entry 3 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,375 Underlying: Common Stock · 54,375 shares Expires 2019-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:13 UTC |
Graves KurtEVP, Chief Commercial Officer
|
GrantCommon Stock | 12,084 | $0.01 | $120.84 |
DisclosureSEC source: 0000875320-09-000003 · edgar.xml · nonDerivative · entry 1 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,248 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2013, subject to 50% acceleration upon filing a new drug application with the FDA for telaprevir and 50% acceleration upon the approval of a new drug application for telaprevir. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:15 UTC |
BOGER KENNETH SSVP & General Counsel
|
GrantStock Option · Derivative | 45,750 | $0.00 Strike: $33.55 | $0.00 |
DisclosureSEC source: 0000875320-09-000004 · edgar.xml · derivative · entry 4 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2019-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:15 UTC |
BOGER KENNETH SSVP & General Counsel
|
GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-09-000004 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,683 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2013, subject to 50% acceleration upon filing a new drug application with the FDA for telaprevir and 50% acceleration upon the approval of a new drug application for telaprevir. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:18 UTC |
SMITH IAN FEVP & CFO
|
GrantStock Option · Derivative | 54,375 | $0.00 Strike: $33.55 | $0.00 |
DisclosureSEC source: 0000875320-09-000005 · edgar.xml · derivative · entry 5 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,375 Underlying: Common Stock · 54,375 shares Expires 2019-02-04 F6 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:18 UTC |
SMITH IAN FEVP & CFO
|
GrantCommon Stock | 12,084 | $0.01 | $120.84 |
DisclosureSEC source: 0000875320-09-000005 · edgar.xml · nonDerivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,535 F5 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2013, subject to 50% acceleration upon filing a new drug application with the FDA for telaprevir and 50% acceleration upon the approval of a new drug application for telaprevir. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:19 UTC |
MUELLER PETEREVP Drug Innov.& Realiz, CSO
|
GrantStock Option · Derivative | 54,375 | $0.00 Strike: $33.55 | $0.00 |
DisclosureSEC source: 0000875320-09-000006 · edgar.xml · derivative · entry 5 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,375 Underlying: Common Stock · 54,375 shares Expires 2019-02-04 F6 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:19 UTC |
MUELLER PETEREVP Drug Innov.& Realiz, CSO
|
GrantCommon Stock | 12,084 | $0.01 | $120.84 |
DisclosureSEC source: 0000875320-09-000006 · edgar.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,356 F5 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2013, subject to 50% acceleration upon filing a new drug application with the FDA for telaprevir and 50% acceleration upon the approval of a new drug application for telaprevir. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:21 UTC |
BOGER JOSHUA SDirector · CEO
|
GrantStock Option · Derivative | 236,000 | $0.00 Strike: $33.55 | $0.00 |
DisclosureSEC source: 0000875320-09-000007 · edgar.xml · derivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,000 Underlying: Common Stock · 236,000 shares Expires 2019-02-04 F3 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:21 UTC |
BOGER JOSHUA SDirector · CEO
|
GrantCommon Stock | 47,201 | $0.01 | $472.01 |
DisclosureSEC source: 0000875320-09-000007 · edgar.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,142,245 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2013, subject to 50% acceleration upon filing a new drug application with the FDA for telaprevir and 50% acceleration upon the approval of a new drug application for telaprevir. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:23 UTC |
GARRISON RICHARD CSVP and Catalyst
|
GrantStock Option · Derivative | 45,750 | $0.00 Strike: $33.55 | $0.00 |
DisclosureSEC source: 0000875320-09-000008 · edgar.xml · derivative · entry 3 GARRISON RICHARD C · CIK 0001256466 · SVP and Catalyst 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2019-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:23 UTC |
GARRISON RICHARD CSVP and Catalyst
|
GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-09-000008 · edgar.xml · nonDerivative · entry 1 GARRISON RICHARD C · CIK 0001256466 · SVP and Catalyst 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,437 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2013, subject to 50% acceleration upon filing a new drug application with the FDA for telaprevir and 50% acceleration upon the approval of a new drug application for telaprevir. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:26 UTC |
Emmens MatthewDirector · President
|
GrantStock Option · Derivative | 549,000 | $0.00 Strike: $33.55 | $0.00 |
DisclosureSEC source: 0000875320-09-000009 · edgar.xml · derivative · entry 2 Emmens Matthew · CIK 0001298332 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,000 Underlying: Common Stock · 549,000 shares Expires 2019-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:26 UTC |
Emmens MatthewDirector · President
|
GrantCommon Stock | 134,129 | $0.01 | $1,341.29 |
DisclosureSEC source: 0000875320-09-000009 · edgar.xml · nonDerivative · entry 1 Emmens Matthew · CIK 0001298332 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,129 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2012. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:27 UTC |
Kelly LisaSVP, Human Resources
|
GrantStock Option · Derivative | 45,750 | $0.00 Strike: $33.55 | $0.00 |
DisclosureSEC source: 0000875320-09-000010 · edgar.xml · derivative · entry 3 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2019-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:27 UTC |
Kelly LisaSVP, Human Resources
|
GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-09-000010 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,299 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2013, subject to 50% acceleration upon filing a new drug application with the FDA for telaprevir and 50% acceleration upon the approval of a new drug application for telaprevir. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:28 UTC |
Sachdev AmitSVP, Public Policy,Gov Affairs
|
GrantStock Option · Derivative | 61,000 | $0.00 Strike: $33.55 | $0.00 |
DisclosureSEC source: 0000875320-09-000011 · edgar.xml · derivative · entry 3 Sachdev Amit · CIK 0001406338 · SVP, Public Policy,Gov Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,000 Underlying: Common Stock · 61,000 shares Expires 2019-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:28 UTC |
Sachdev AmitSVP, Public Policy,Gov Affairs
|
GrantCommon Stock | 12,200 | $0.01 | $122.00 |
DisclosureSEC source: 0000875320-09-000011 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Public Policy,Gov Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,366 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2013, subject to 50% acceleration upon filing a new drug application with the FDA for telaprevir and 50% acceleration upon the approval of a new drug application for telaprevir. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:30 UTC |
Lewis-Hall Freda CEVP, Medicines Development
|
GrantStock Option · Derivative | 90,625 | $0.00 Strike: $33.55 | $0.00 |
DisclosureSEC source: 0000875320-09-000012 · edgar.xml · derivative · entry 2 Lewis-Hall Freda C · CIK 0001437909 · EVP, Medicines Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,625 Underlying: Common Stock · 90,625 shares Expires 2019-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:30 UTC |
Lewis-Hall Freda CEVP, Medicines Development
|
GrantCommon Stock | 12,084 | $0.01 | $120.84 |
DisclosureSEC source: 0000875320-09-000012 · edgar.xml · nonDerivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · EVP, Medicines Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,584 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2013, subject to 50% acceleration upon filing a new drug application with the FDA for telaprevir and 50% acceleration upon the approval of a new drug application for telaprevir. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:32 UTC |
Silva Paul MV.P. and Corporate Controller
|
GrantStock Option · Derivative | 15,000 | $0.00 Strike: $33.55 | $0.00 |
DisclosureSEC source: 0000875320-09-000013 · edgar.xml · derivative · entry 3 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2019-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:32 UTC |
Silva Paul MV.P. and Corporate Controller
|
GrantCommon Stock | 2,000 | $0.01 | $20.00 |
DisclosureSEC source: 0000875320-09-000013 · edgar.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,750 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2013, subject to 50% acceleration upon filing a new drug application with the FDA for telaprevir and 50% acceleration upon the approval of a new drug application for telaprevir. Read SEC document |
| February 04, 2009 Filed Feb 6, 2009 21:18 UTC |
SMITH IAN FEVP & CFO
|
SaleCommon Stock | 474 | $34.11 | $16,168.14 |
DisclosureSEC source: 0000875320-09-000005 · edgar.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,451 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan established under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $34.11 (range $34.05 to $34.16). F4 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2009 Filed Feb 6, 2009 21:18 UTC |
SMITH IAN FEVP & CFO
|
SaleCommon Stock | 2,376 | $33.51 | $79,619.76 |
DisclosureSEC source: 0000875320-09-000005 · edgar.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,925 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $33.51 (range $33.05 to $33.88). F4 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2009 Filed Feb 6, 2009 21:19 UTC |
MUELLER PETEREVP Drug Innov.& Realiz, CSO
|
SaleCommon Stock | 218 | $34.07 | $7,427.26 |
DisclosureSEC source: 0000875320-09-000006 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,272 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $34.07 (range $34.02 to $34.13). F4 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2009 Filed Feb 6, 2009 21:19 UTC |
MUELLER PETEREVP Drug Innov.& Realiz, CSO
|
SaleCommon Stock | 900 | $33.55 | $30,195.00 |
DisclosureSEC source: 0000875320-09-000006 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,490 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $33.55 (range $32.96 to $33.94). F4 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 29, 2009 Filed Jan 30, 2009 21:30 UTC |
BRANDT ERICDirector
|
Exercise / conversionStock Options · Derivative | 7,500 | $0.00 Strike: $9.09 | $0.00 |
DisclosureSEC source: 0000875320-09-000002 · edgar.xml · derivative · entry 5 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2015-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| January 29, 2009 Filed Jan 30, 2009 21:30 UTC |
BRANDT ERICDirector
|
Exercise / conversionStock Options · Derivative | 20,000 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0000875320-09-000002 · edgar.xml · derivative · entry 4 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2013-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| January 29, 2009 Filed Jan 30, 2009 21:30 UTC |
BRANDT ERICDirector
|
SaleCommon Stock | 27,500 | $33.00 | $907,500.00 |
DisclosureSEC source: 0000875320-09-000002 · edgar.xml · nonDerivative · entry 3 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Mr. Brandt's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 29, 2009 Filed Jan 30, 2009 21:30 UTC |
BRANDT ERICDirector
|
Exercise / conversionCommon Stock | 7,500 | $9.09 | $68,175.00 |
DisclosureSEC source: 0000875320-09-000002 · edgar.xml · nonDerivative · entry 2 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2009 Filed Jan 30, 2009 21:30 UTC |
BRANDT ERICDirector
|
Exercise / conversionCommon Stock | 20,000 | $13.22 | $264,400.00 |
DisclosureSEC source: 0000875320-09-000002 · edgar.xml · nonDerivative · entry 1 BRANDT ERIC · CIK 0001190639 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2009 Filed Jan 16, 2009 17:35 UTC |
MUELLER PETEREVP Drug Innov.& Realiz, CSO
|
Exercise / conversionStock Option · Derivative | 2,400 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0000875320-09-000001 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,400 shares Expires 2013-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| January 15, 2009 Filed Jan 16, 2009 17:35 UTC |
MUELLER PETEREVP Drug Innov.& Realiz, CSO
|
SaleCommon Stock | 2,400 | $29.63 | $71,112.00 |
DisclosureSEC source: 0000875320-09-000001 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,390 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $29.63 (range $29.19 to $30.05). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 15, 2009 Filed Jan 16, 2009 17:35 UTC |
MUELLER PETEREVP Drug Innov.& Realiz, CSO
|
Exercise / conversionCommon Stock | 2,400 | $9.07 | $21,768.00 |
DisclosureSEC source: 0000875320-09-000001 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2008 Filed Dec 22, 2008 16:50 UTC |
Lewis-Hall Freda CEVP, Medicines Development
|
SaleCommon Stock | 1,250 | $29.90 | $37,375.00 |
DisclosureSEC source: 0000875320-08-000097 · edgar.xml · nonDerivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · EVP, Medicines Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 F1 · kind: Transaction made pursuant to Dr. Lewis-Hall's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $29.90 (range $29.46 to $30.19). F3 · price: Dr. Lewis-Hall undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2008 Filed Dec 16, 2008 18:23 UTC |
GARRISON RICHARD CSVP and Catalyst
|
SaleCommon Stock | 1,595 | $25.24 | $40,257.80 |
DisclosureSEC source: 0000875320-08-000095 · edgar.xml · nonDerivative · entry 2 GARRISON RICHARD C · CIK 0001256466 · SVP and Catalyst 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,307 F1 · kind: Transaction made pursuant to Mr. Garrison's company approved trading plan established under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $25.24 (range $25.04 to $25.81). F4 · price: Mr. Garrison undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2008 Filed Dec 16, 2008 18:23 UTC |
GARRISON RICHARD CSVP and Catalyst
|
SaleCommon Stock | 380 | $24.80 | $9,424.00 |
DisclosureSEC source: 0000875320-08-000095 · edgar.xml · nonDerivative · entry 1 GARRISON RICHARD C · CIK 0001256466 · SVP and Catalyst 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,902 F1 · kind: Transaction made pursuant to Mr. Garrison's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $24.80 (range $24.79 to $24.80). F4 · price: Mr. Garrison undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.